Skip to content

LBRX LBRX Depreciation

Depreciation at other companies

MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
Alto Neuroscience logo
Alto NeuroscienceANRO
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
Axsome Therapeutics logo
Axsome TherapeuticsAXSM

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$888.98M+163%
Enterprise value$571.77M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's depreciation?
LBRX (LBRX) reported depreciation of $82K in Q1 2026.